Dear Doctor Letter (Rote-Hand-Brief) on filgrastim, pegfilgrastim, lipegfilgrastim and lenograstim: new warnings regarding aortitis associated with the use of granulocyte colony-stimulating factors (G-CSF)
2018.06.25
Active substance: filgrastim, pegfilgrastim, lipegfilgrastim, lenograstim
In agreement with the Federal Institute for Drugs and Medical Devices (BFARM), the marketing authorisation holders are circulating information on the risk of aortitis associated with the administration of granulocyte colony-stimulating factors (G-CSF).
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN